Comprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer

• Published in: BMC medical genomics Vol. 16; no. 1; pp. 1 - 234
• Main Authors: Zhang, Luyao, Yu, Shuang, Hong, Shubin, Xiao, Xi, Liao, Zhihong, Li, Yanbing, Xiao, Haipeng
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 05.10.2023; BioMed Central; BMC
• Subjects: Analysis; B cells; Biomarker; Biomarkers; BTNL9; Butyrophilin; Cancer; Care and treatment; Chemokines; Cytokines; Datasets; Development and progression; Enhancers; Epigenetics; Gene expression; Gene set enrichment analysis; Genes; Genetic aspects; Genomes; Genomics; Genotypes; Immune checkpoint; Immune infiltration; Infiltration; Medical prognosis; Melanoma; Metastases; Metastasis; Nomograms; Oncology, Experimental; Papillary thyroid cancer; Prevention; Prognosis; Proteins; Risk factors; RNA; RNA sequencing; Software; Statistical analysis; Survival analysis; Therapeutic targets; Thyroid cancer; Tumors; Ultrasonic imaging; China
• ISSN: 1755-8794; 1755-8794
• DOI: 10.1186/s12920-023-01676-8

Thyroid cancer (THCA) is the most common type of endocrine cancers, and the disease recurrences were usually associated with the risks of metastasis and fatality. Butyrophilin-like protein 9 (BTNL9) is a member of the immunoglobulin families. This study investigated the prognostic role of BTNL9 in THCA. Gene enhancers of BTNL9 were identified by interrogating H3K27ac ChIP-seq and RNA-seq data of papillary thyroid cancer (PTC) and benign thyroid nodule (BTN) tissues. Meanwhile, BTNL9 expression level was verified by qRT-PCR in 30 pairs of primary THCA and adjacent normal tissues. Clinicopathological and RNA sequencing data were obtained from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) to analyze the relations between BTNL9 expression and immune cell infiltration, chemokines/cytokines, immune checkpoint genes, clinical parameters and prognosis values. Besides, survival analysis combining BTNL9 expression and immune cell infiltration scores was conducted. Functional enrichment analysis was performed to investigate the potential biological mechanisms. Cox regression analyses were used to explore independent clinical indicators, and a nomogram model incorporating BTNL9 expression with clinical parameters was established. BTNL9 showed significantly stronger H3K27ac modifications in BTN than PTC tissues at the promoter region (chr5: 181,035,673-181,047,436) and gene body (chr5: 181,051,544-181,054,849). The expression levels of BTNL9 were significantly down-regulated in THCA samples compared to normal tissues, and were strongly associated with different tumor stages, immune cell infiltrations, chemokines/cytokines and immune checkpoint genes in THCA. Functional enrichment analyses indicated that BTNL9 was involved in immune-related and cancer-related pathways. The Kaplan-Meier analysis showed lower BTNL9 expression was associated with poorer progression-free interval (PFI). BTNL9 expression and pathologic stages were independent prognostic indicators of PFI in THCA. The results implied an important role of BTNL9 in the tumor progression, with the possibility of serving as a novel prognostic biomarker and a potential therapeutic target for THCA.